Clifford Reid, CEO of Complete Genomics, said in a keynote at Bio-IT World that their data would allow us to understand cancer in five years. I think if he'd made that statement at AACR he would have a hard time. Cancer researchers are glad for this kind of data but they are also aware that it's not worth much if you can't use it to gain biological knowledge. Even though there are IT and informatics challenges from these new technologies, the biggest challenges are going to be how to get this data into a form that it can be assessed by those that have expertise in the biology of disease.
Trends in Biotechnology
Notes from the 2009 BIO-IT World Conference & Expo
Great people, fascinating topics in sessions and conversations...we churned through a lot of data (using grey matter and discussion, those fruitful old-fashioned processors) and have arrived at our listing of the top trends in our field....
What Next-Gen Sequencing Data Can and Can't Do
I was fortunate enough to attend the American Association of Cancer Researchers (AACR) meeting in Denver the week before Bio-IT World. Bio-IT World was filled with talks and discussions about how technologies such as next-generation sequencing, which have the potential to generate huge amounts of data, are requiring changes in IT and informatics. But a theme at AACR, from several speakers, was that data itself does not solve the problems of understanding the underlying biology of disease. And understanding the biology is how new therapeutics and diagnostics are going to come about.
posted by Will FitzHugh at
4:00 PM
0 Comments:
Post a Comment
<< Home